ALX Oncology Holdings, Inc. (ALXO)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Apr 21, 2025

$0.57

P/E Ratio

N/A

Market Cap

$30.23M

Description
Add to research
View more

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Metrics
Add to research
View more

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerALXO
  • Price$0.5662+2.95%

Trading Information

  • Market cap$30.23M
  • Float63.67%
  • Average Daily Volume (1m)504,069
  • Average Daily Volume (3m)978,907
  • EPS-$2.58

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$134.85M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$141.60M
  • EV-$23.65M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.26
  • Debt/Equity14.94
Documents
Add to research
View more
SEC Filings
8-K (2025-03-06)
8-K (2025-03-05)
8-K (2025-01-22)
8-K (2025-01-17)
8-K (2024-11-14)
8-K (2024-11-07)
8-K (2024-10-04)
8-K (2024-08-08)
8-K (2024-08-06)
8-K (2024-06-17)
8-K (2024-05-09)
8-K (2024-05-02)
8-K (2024-03-07)
8-K (2023-12-26)
8-K (2023-11-13)
8-K (2023-10-06)
8-K (2023-10-04)
8-K (2023-09-06)
8-K (2023-08-10)
8-K (2023-06-20)
8-K (2023-05-11)
8-K (2023-03-13)
8-K (2023-03-09)
10-Q (2024-11-07)
10-Q (2024-08-12)
10-Q (2024-05-09)
10-Q (2023-11-13)
10-Q (2023-08-10)
10-Q (2023-05-11)
10-K (2025-03-06)
10-K (2024-03-07)
10-K (2023-03-09)
Factset Street Account
ALX Oncology to host investor call and webcast on 3-Oct-23 to share interim Phase 2 ASPEN-06 clinical trial results of Evorpacept ($4.85, 0.00) (2023-10-02T20:09:27Z)
ALX Oncology reports interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer ($4.81, 0.00) (2023-10-03T10:02:52Z)
ALX Oncology Holdings reports Q3 GAAP EPS ($1.24) vs FactSet ($0.85) [7 est, ($0.99)-(0.72)] ($8.41, 0.00) (2023-11-13T21:10:50Z)
ALX Oncology Holdings offering of 7.4M common shares and pre-funded warrants to purchase 1.3M shares priced through Piper Sandler and Cantor ($6.38, 0.00) (2023-10-05T12:02:36Z)